The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins
Open accessAbstract
Importance: There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. Objective: To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Design, Setting, and Participants: Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). Main Outcomes and Measures: Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). Results: In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43 for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US Preventive Services Task Force screening criteria, the integrated risk prediction model yielded a specificity of 0.95 compared with 0.86 for the smoking model. Conclusions and Relevance: This study provided a proof of principle in showing that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638
Self-citation
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.023 · Cited by 539
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives
Oudkerk, M., Liu, S., Heuvelmans, M. A., Walter, J. E., & Field, J. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00432-6 · Cited by 519
Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24994-w · Cited by 472
Adams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01694-4 · Cited by 467
Metadata
- Authors
- Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, F., Sun, N., Bantis, L. E., Muller, D. C., Li, P., Taguchi, A., Dhillon, D., Kundnani, D. L., Patel, N. J., Yan, Q., Byrnes, G., Moons, K. G. M., Tjønneland, A., Panico, S., Agnoli, C., Vineis, P., Palli, D., Bueno-de-Mesquita, B., Peeters, P. H., Agudo, A., Huerta, J. M., Dorronsoro, M., Barranco, M. R., Ardanaz, E., Travis, R. C., Byrne, K. S., Boeing, H., Steffen, A., Kaaks, R., Hüsing, A., Trichopoulou, A., Lagiou, P., La Vecchia, C., Severi, G., Boutron-Ruault, M.-C., Sandanger, T. M., Weiderpass, E., Nøst, T. H., Tsilidis, K., Riboli, E., Grankvist, K., Johansson, M., Goodman, G. E., Feng, Z., Brennan, P., Johansson, M., & Hanash, S. M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-10-11
- Volume
- 4
- Issue
- 10
- Pages
- e182078
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2862606086
- Cited by
- 169
- References
- 2
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. https://app.cochat.ai/papers/10.1001/jamaoncol.2018.2078
- The paper
- Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, F., Sun, N., Bantis, L. E., Muller, D. C., Li, P., Taguchi, A., Dhillon, D., Kundnani, D. L., Patel, N. J., Yan, Q., Byrnes, G., Moons, K. G. M., Tjønneland, A., Panico, S., Agnoli, C., Vineis, P., Palli, D., Bueno-de-Mesquita, B., . . . Hanash, S. M. (2018). Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.2078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.